Protocol Ledger

NCT05325593 · Phase III · ACTIVE NOT RECRUITING

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Interventional Phase III clinical trial protocol NCT05325593 sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-02 Enrollment: 129 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05325593
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)129 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05325593
Protocol FieldVerified Registry Value
NCT IdentifierNCT05325593
Consolidated Lead SponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment129 participants (ACTUAL)
Registered Start Date2022-12-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI